VALENTINA AKOH: Open Payments
NPI 1982374351 · LAS VEGAS, NV. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$4,435 in 204 payments from 15 companies in 2025. Trend: 2023 $2,586 · 2024 $2,741 · 2025 $4,435
Food & beverage: $4,435
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 32 | $739 |
| Otsuka America Pharmaceutical, Inc. | 28 | $705 |
| Alkermes, Inc. | 20 | $548 |
| E.R. Squibb & Sons, L.L.C. | 20 | $449 |
| Vanda Pharmaceuticals Inc. | 11 | $382 |
| ABBVIE INC. | 27 | $372 |
| Neurocrine BioSciences, Inc. | 16 | $337 |
| Janssen Pharmaceuticals, Inc | 11 | $227 |
| Supernus Pharmaceuticals, Inc. | 14 | $169 |
| Axsome Therapeutics, Inc. | 6 | $127 |
Products named: CAPLYTA, ARISTADA, REXULTI, COBENFY, FANAPT, VRAYLAR, INGREZZA, Qelbree.
Industry payments across NV — which companies pay providers there.
